About 6 months after the FDA gave the nod to Vertex Pharmaceuticals' pricey drug Kalydeco, the European Commission also approved the treatment for patients with cystic fibrosis that have a certain genetic mutation.
Vertex Pharmaceuticals had to revise data on its proposed combination therapy for cystic fibrosis after learning an initial analysis was faulty.
Social media buzz can be both good and bad, and smart companies want to keep track of both.
Outgoing Vertex Pharmaceuticals CEO Matthew Emmens saw his 2011 compensation drop slightly, despite the company's successful launch of its new hepatitis C drug, Incivek.
Merck ($MRK) has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck...
How one father's loss turned into gain for cystic fibrosis patients and Vertex Pharmaceuticals ($VRTX): After the death of his son, Boston businessman Joe O'Donnell spent years raising $250 million
Last week, Vertex Pharmaceuticals ($VRTX) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as
Another day, another round of earnings calls. Today's roundup includes Allergan, which received a boost from Botox, a widely known wrinkle-fighter that is now garnering approvals around the world for
Vertex Pharmaceuticals ($VRTX) achieved another major milestone with FDA's approval of its cystic fibrosis therapy Kalydeco. The "breakthrough" product is the first to address CF's...
No question that Vertex Pharmaceuticals ($VRTX) needs another hit to follow its new hepatitis C drug Incivek. But that's just one of the things on the to-do list for incoming CEO Jeffrey Leiden, who